REGN Stock Chart & Fundamental Analysis

Interactive Chart

About Regeneron Pharmaceuticals

Name

Regeneron Pharmaceuticals

CEO

Leonard S. Schleifer

Website

www.regeneron.com

Industry

Healthcare

Year Founded

1988

Employees

15,158

Regeneron Pharmaceuticals, Inc. develops and markets biologic medicines as a biotechnology company listed on NASDAQ under REGN. Its portfolio spans eye disease, immunology, oncology, cardiovascular and infectious-disease therapies, and it generated $14.3 billion of revenue in FY2025 through a portfolio of marketed drugs and clinical-stage product candidates.

Analyst Ratings

Consensus Recommendation

Buy3

Hold3

Sell1

Fundamentals & Financials

Revenue (TTM)

$14.9B

Net Income (TTM)

$4.4B

EPS (TTM)

$42.53

ROA (TTM)

10.82%

Current Ratio

3.57

Dividend Yield

0.12%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q1 FY2026	Q4 FY2025	Q3 FY2025
Revenue	$3,605.4M	$3,884.3M	$3,754.3M
Cost of Sales	$669,400K	$584,600K	$521,600K
Gross Profit	$2,936M	$3,299.7M	$3,232.7M
Operating Income	$642,900K	$879,900K	$1,026.8M
Net Income	$727,200K	$844,600K	$1,460M
EPS	$6.99	$8.21	$14.09

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

Regeneron Pharmaceuticals's Technical Indicators Summary

REGN shows a buy orientation underpinned by a firm ADX and strong short‑term momentum readings, with the stock above recent short and medium moving averages while the classic pivot lies below the market. Longer‑term moving averages are higher, producing a mixed multi‑timeframe picture, and MACD is not yet decisively bullish, but volume trends remain supportive and ATR is moderate. Technical takeaway: Buy.

Buy

3 signals

Neutral

3 signals

Sell

1 signal

Overall: Bullish43% Bullish signals

Indicator	Value	Signal	Explanation
RSI (14)	59.66	Neutral	RSI (59.66) is neutral.
Stochastic %K (14, 3, 3)	77.40	Neutral	Stochastic (77.40) is neutral.
CCI (20)	178.99	Buy	CCI (178.99) > 100, indicating strong upward momentum.
WPR (14)	-1.10	Sell	Williams %R (-1.10) > -20, indicating overbought.
Momentum (10)	46.34	Buy	Momentum (46.34) is positive.
MFI	60.57	Neutral	MFI (60.57) is neutral.
MACD Level (12, 26)	-4.63	Neutral	Potential bullish reversal: MACD (-4.63) crossed above signal but is still negative.
Bollinger Bands	$596.19 - $644.40	Sell	Price ($654.27) is above the upper band ($644.40).
ATR (14)	$16.73 (2.56%)	Neutral	Moderate Volatility (2.56%).
ADX (14)	28.65	Buy	Strong uptrend (ADX > 25) with bullish directional movement. ADX(28.65), +DI(23.00), -DI(18.65)
OBV	742,641	Buy	Bullish volume pressure: OBV is above its 20-day SMA. OBV(742,641), 20D-SMA-OBV(-3,625,653)
Classic Pivot Point	$627.15	Buy	Price ($654.27) has broken above resistance R1 ($630.42) — bullish breakout potential.
Fibonacci Pivot Point	$627.15	Buy	Price ($654.27) has broken above resistance R1 ($630.58) — bullish breakout potential.
Simple Moving Averages	$620.29 - $710.91(5 indicators)	Sell	SMA group: 3/5 bearish, 2 bullish, 0 neutral. Price below key SMA averages.
Exponential Moving Averages	$627.95 - $680.40(5 indicators)	Buy	EMA group: 3/5 bullish, 2 bearish, 0 neutral. Price above key EMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

Despite intraday swings, REGN preserved the bulk of its 4.73% gap versus yesterday. By the close, sector strength was clear, with a 2.65% gain underpinning risk appetite. The day wrapped with earnings still looming for REGN, 28 days ahead on 30 July.

Trading Volume

vs S&P 500 Today

Strong Outperformance

+29.88%

52-Week Position

Mid-range

42.2%

Updated: July 2, 2026 at 20:18 UTC